logo
Plus   Neg
Share
Email

6 Top Losers In Healthcare Sector (LXRX, XBIO, ONCY...)

pharmadown july29 lt

The following are some of the healthcare stocks that posted the biggest percentage decline on Monday.

1. Lexicon Pharmaceuticals Inc. (LXRX)

Lost 70.30% to close Monday's (July 29) trading at $1.69.

News: Sanofi has decided to terminate its partnership with Lexicon Pharma that was signed in 2015 for the development and commercialization of Zynquista (sotagliflozin), a potential treatment option for people with diabetes.

Sanofi also provided topline results from three Phase 3 trials of Zynquista, namely SOTA-MET, SOTA-CKD3 and SOTA-CKD4.

-- In SOTA-MET, Zynquista 400 mg demonstrated a statistically significant reduction in blood sugar control (A1C) compared to placebo at 26 weeks in patients on metformin.
-- In SOTA-CKD3, Zynquista 400 mg showed a statistically significant reduction in A1C in the entire population of patients with moderate (stage 3) chronic kidney disease (CKD) and in the subpopulation of patients with a glomerular filtration rate of 45-<60 mL/min/1.73m2 (stage 3A CKD) compared to placebo at 26 weeks. Although Zynquista demonstrated numerical improvement on A1C, a statistically significant reduction in A1C was not achieved in the subpopulation of patients with a glomerular filtration rate of 30-<45 mL/min/1.73m2 (stage 3B CKD).
-- In SOTA-CKD4, Zynquista 400 mg achieved a clinically meaningful effect but narrowly missed statistical significance on A1C reduction versus placebo in patients with severe (stage 4) CKD at 26 weeks.

2. Xenetic Biosciences Inc. (XBIO)

Xenetic Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, research, and development of next-generation biologic drugs and novel orphan oncology therapeutics.

Lost 14.03% to close Monday's trading at $2.39.

News: No news

Recent event:

-- On July 22, 2019, the Company announced that it has closed its previously announced $15.0 million underwritten public offering.

About 2.3 million shares of its common stock and warrants to purchase up to 2.3 million shares of the common stock were sold in the offering. Each share of common stock was sold together with one warrant to purchase one share of common stock at a combined price to the public of $6.50 per share and warrant.

-- On June 25, 2019, a one-for-twelve reverse stock split of the Company's issued and outstanding common stock was implemented.

3. Neon Therapeutics Inc. (NTGN)

Neon Therapeutics is focused on developing neoantigen-targeted therapies, dedicated to transforming the treatment of cancer.

The Company's most advanced product candidate is NEO-PV-01, a personal neoantigen vaccine, under phase Ib trials, dubbed NT-001, NT-002, NT-003, and NT-004.

Lost 11.62% to close Monday's trading at $2.89.

News: No news

Clinical Trials & Near-term Catalysts:

NT-001 is exploring the combination of NEO-PV-01 and Bristol Myers' Opdivo in patients with metastatic or advanced melanoma, lung, or bladder cancer. The top-line clinical results, including 12-month follow-up, from this trial, were reported in July 2019. The study demonstrated prolonged and consistent improvements in progression-free survival (PFS) across all three distinct tumor types.

The study dubbed NT-002 is testing the combination of NEO-PV-01 and Merck's Keytruda in patients with advanced or metastatic nonsquamous non-small cell lung carcinoma. The immune monitoring and clinical outcome data from this trial are anticipated by the end of Q3 2020.

NT-003 is evaluating NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab in patients with advanced or metastatic melanoma. Immune monitoring data is expected in the second half of 2020.

4. Entera Bio Ltd. (ENTX)

Entera Bio is a clinical-stage biopharmaceutical company focused on developing orally-delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical needs.

Lost 16.46% to close Monday's trading at $3.30.

News: No news

Clinical Trials & Near-term Catalysts:

-- A phase II clinical trial of Oral PTH 1-34 for hypoparathyroidism is underway. The Company reported positive results from Part I of this study last November. Part 1 of the phase II trial in patients with hypoparathyroidism was designed to evaluate the PK and PD profiles of Oral PTH (1-34) and injectable PTH (1-84), Natpara.
-- A phase II study of osteoporosis drug candidate EB613 was initiated as recently as July 2, 2019.

5. Oncolytics Biotech Inc. (ONCY)

Oncolytics is developing Pelareorep, an intravenously delivered immuno-oncolytic virus (IOV) that kills cancer.

Lost 10.63% to close Monday's trading at $1.43.

News: No news

Clinical Trials & Near-term Catalyst:

An open-label window-of-opportunity study combining Pelareorep and Tecentriq in early-stage breast cancer, dubbed AWARE-1, is underway. The AWARE-1 trial is designed to enroll 38 patients into five cohorts.

On July 23, 2019, the Company announced the completion of the three patient run-in for the AWARE-1 study. The preliminary results demonstrated viral replication and promotion of inflammation following systemic administration of Pelareorep when combined with Tecentriq.

Interim data from the AWARE-1 trial is expected to be presented at a scientific conference before the end of the year.

6. Hoth Therapeutics Inc. (HOTH)

Hoth Therapeutics is a development-stage biopharmaceutical company developing therapeutics for patients suffering from indications such as atopic dermatitis and dermatological and chronic wound disorders.

Lost 9.72% to close Monday's trading at $5.57.

News: No news

Recent event:

On July 22, 2019, the Company announced positive initial results of its Pilot Study of BioLexa Platform's application on diabetic skin ulcers in an animal model. Hoth has exclusive worldwide rights to the BioLexa Platform.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT